The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
Abstract
The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish 177 Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Self-citationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Self-citationGastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Self-citationKwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Self-citationReubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Pavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Self-citationZaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Self-citationKwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Self-citationImhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
Sundin, A., Arnold, R., Baudin, E., Cwikla, J. B., Eriksson, B., Fanti, S., Fazio, N., Giammarile, F., Hicks, R. J., Kjaer, A., et al. (2017) · Neuroendocrinology · doi:10.1159/000471879 · Cited by 501
Self-citationBinderup, T., Knigge, U., Loft, A., Federspiel, B., & Kjaer, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1759 · Cited by 489
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. L., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100574 · Cited by 471
Self-citationBodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2893-5 · Cited by 465
Self-citationTumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A. R., & Mueller‐Brand, J. (2002) · PubMed · Cited by 445
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 435
Self-citationPeptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Bodei, L., Cremonesi, M., Grana, C. M., Fazio, N., Iodice, S., Baio, S. M., Bartolomei, M., Lombardo, D., Ferrari, M. E., Sansovini, M., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1902-1 · Cited by 424
Self-citationYttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maecke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 420
Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., & Mueller-Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396
Tang, L. H., Basturk, O., Sue, J. J., & Klimstra, D. S. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000662 · Cited by 382
Valkema, R., Pauwels, S. A., Kvols, L. K., Kwekkeboom, D. J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P. P. M., Bakker, W. H., et al. (2005) · PubMed · Cited by 332
Self-citationKRENNING, E. P., KOOIJ, P. P. M., BAKKER, W. H., BREEMAN, W. A. P., POSTEMA, P. T. E., KWEKKEBOOM, D. J., OEI, H. Y., de JONG, M., VISSER, T. J., REIJS, A. E. M., et al. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17300.x · Cited by 313
Self-citationValkema, R., Pauwels, S., Kvols, L. K., Barone, R., Jamar, F., Bakker, W. H., Kwekkeboom, D. J., Bouterfa, H., & Krenning, E. P. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.01.001 · Cited by 313
Self-citation90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
Bushnell, D. L., O'Dorisio, T. M., O'Dorisio, M. S., Menda, Y., Hicks, R. J., Van Cutsem, E., Baulieu, J.-L., Borson-Chazot, F., Anthony, L., Benson, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8585 · Cited by 306
Self-citationBodei, L., Cremonesi, M., Zoboli, S., Grana, C., Bartolomei, M., Rocca, P., Caracciolo, M., Mäcke, H. R., Chinol, M., & Paganelli, G. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1023-y · Cited by 305
Self-citationConsensus on biomarkers for neuroendocrine tumour disease
Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00186-2 · Cited by 283
Self-citationIndium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., & McCarthy, K. E. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31769 · Cited by 279
Perren, A., Couvelard, A., Scoazec, J.-Y., Costa, F., Borbath, I., Delle Fave, G., Gorbounova, V., Gross, D., Grossman, A., Jensen, R. T., et al. (2017) · Neuroendocrinology · doi:10.1159/000457956 · Cited by 250
Self-citationCombination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong, M., Breeman, W. A. P., Valkema, R., Bernard, B. F., & Krenning, E. P. (2005) · PubMed · Cited by 244
Self-citationJamar, F., Barone, R., Mathieu, I., Walrand, S., Labar, D., Carlier, P., Camps, J., Schran, H., Chen, T., Smith, M. C., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1117-1 · Cited by 240
Self-citationKunikowska, J., Królicki, L., Hubalewska-Dydejczyk, A., Mikołajczak, R., Sowa-Staszczak, A., & Pawlak, D. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1833-x · Cited by 238
Garin, E., Le Jeune, F., Devillers, A., Cuggia, M., de Lajarte-Thirouard, A.-S., Bouriel, C., Boucher, E., & Raoul, J.-L. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057505 · Cited by 234
Claringbold, P. G., Brayshaw, P. A., Price, R. A., & Turner, J. H. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1631-x · Cited by 210
Garkavij, M., Nickel, M., Sjögreen‐Gleisner, K., Ljungberg, M., Ohlsson, T., Wingårdh, K., Strand, S., & Tennvall, J. (2010) · Cancer · doi:10.1002/cncr.24796 · Cited by 205
Ezziddin, S., Khalaf, F., Vanezi, M., Haslerud, T., Mayer, K., Al Zreiqat, A., Willinek, W., Biersack, H.-J., & Sabet, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2677-3 · Cited by 189
Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K. T., Mäcke, H. R., Müller-Brand, J., Rochlitz, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2151 · Cited by 189
Bahri, H., Laurence, L., Edeline, J., Leghzali, H., Devillers, A., Raoul, J.-L., Cuggia, M., Mesbah, H., Clement, B., Boucher, E., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.144386 · Cited by 186
Esser, J. P., Krenning, E. P., Teunissen, J. J. M., Kooij, P. P. M., van Gameren, A. L. H., Bakker, W. H., & Kwekkeboom, D. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0172-9 · Cited by 179
Self-citationKhan, S., Krenning, E. P., van Essen, M., Kam, B. L., Teunissen, J. J., & Kwekkeboom, D. J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.087932 · Cited by 179
Self-citationCwikla, J. B., Sankowski, A., Seklecka, N., Buscombe, J. R., Nasierowska-Guttmejer, A., Jeziorski, K. G., Mikolajczak, R., Pawlak, D., Stepien, K., & Walecki, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp372 · Cited by 173
Self-citationClaringbold, P. G., Price, R. A., & Turner, J. H. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1276 · Cited by 163
A Case History: NMR Studies of the Structure of a Small Protein, ω-Conotoxin MVIIA
MacLachlan, L. K., Middleton, D. A., Edwards, A. J., & Reid, D. G. (2003) · Humana Press eBooks · doi:10.1385/0-89603-309-0:337 · Cited by 150
Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
Beauregard, J., Hofman, M. S., Pereira, J. M., Eu, P., & Hicks, R. J. (2011) · Cancer Imaging · doi:10.1102/1470-7330.2011.0012 · Cited by 147
Self-citationBuscombe, J. R., Caplin, M. E., & Hilson, A. J. W. (2003) · PubMed · Cited by 143
van Essen, M., Krenning, E. P., Kam, B. L. R., de Herder, W. W., van Aken, M. O., & Kwekkeboom, D. J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0688-7 · Cited by 138
Self-citationKnigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., et al. (2017) · Neuroendocrinology · doi:10.1159/000458155 · Cited by 136
Self-citationPeptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms
Baum, R. P., Kulkarni, H., & Carreras, C. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.01.002 · Cited by 134
de Keizer, B., van Aken, M. O., Feelders, R. A., de Herder, W. W., Kam, B. L. R., van Essen, M., Krenning, E. P., & Kwekkeboom, D. J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0691-z · Cited by 134
Self-citationHelisch, A., F�rster, G., Reber, H., Buchholz, H., Arnold, R., G�ke, B., Weber, M. M., Wiedenmann, B., Pauwels, S. A., Haus, U., et al. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1561-6 · Cited by 133
Self-citationKidney protection during peptide receptor radionuclide therapy with somatostatin analogues
Rolleman, E. J., Melis, M. L., Valkema, R., Boerman, O. C., Krenning, E. P., & de Jong, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1282-y · Cited by 131
Self-citationChinol, M., Bodei, L., Cremonesi, M., & Paganelli, G. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31563 · Cited by 127
Self-citationPfeifer, A. K., Gregersen, T., Grønbæk, H., Hansen, C. P., Müller‐Brand, J., Bruun, K. H., Krogh, K., Kjær, A., & Knigge, U. (2011) · Neuroendocrinology · doi:10.1159/000324096 · Cited by 127
van Vliet, E. I., van Eijck, C. H. J., de Krijger, R. R., van Dijkum, E. J. M. N., Teunissen, J. J. M., Kam, B. L. R., de Herder, W. W., Feelders, R. A., Bonsing, B. A., Brabander, T., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158899 · Cited by 126
Self-citationPaganelli, G., Sansovini, M., Ambrosetti, A., Severi, S., Monti, M., Scarpi, E., Donati, C., Ianniello, A., Matteucci, F., & Amadori, D. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2735-5 · Cited by 122
Kashyap, R. K., Hofman, M. S., Michael, M., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2906-4 · Cited by 115
Sansovini, M., Severi, S., Ambrosetti, A., Monti, M., Nanni, O., Sarnelli, A., Bodei, L., Garaboldi, L., Bartolomei, M., & Paganelli, G. (2013) · Neuroendocrinology · doi:10.1159/000348394 · Cited by 114
Self-citationBaum, R. P., Kluge, A., Kulkarni, H., Schorr-Neufing, U., Niepsch, K., Bitterlich, N., & van Echteld, C. J. A. (2016) · Theranostics · doi:10.7150/thno.13702 · Cited by 113
90Y–DOTA– D ‐Phe1–Try3– octreotide in therapy of neuroendocrine malignancies
Paganelli, G., Bodei, L., Handkiewicz-Junak, D., Rocca, P. A., Papi, S., Sierra, M. L., Gatti, M., Chinol, M., Bartolomei, M., Fiorenza, M., et al. (2002) · Biopolymers · doi:10.1002/bip.10349 · Cited by 104
Self-citation(2010) · PubMed · Cited by 102
Sabet, A., Dautzenberg, K., Haslerud, T. M., Aouf, A., Sabet, A., Simon, B., Mayer, K. T., Biersack, H., & Ezziddin, S. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3041-6 · Cited by 100
Kong, G., Thompson, M., Collins, M. L., Herschtal, A., Hofman, M. S., Johnston, V. K., Eu, P., Michael, M., & Hicks, R. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2788-5 · Cited by 98
Self-citationHörsch, D., Ezziddin, S., Haug, A. R., Gratz, K. F., Dunkelmann, S., Miederer, M., Schreckenberger, M., Krause, B. J., Bengel, F. M., Bartenstein, P., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.009 · Cited by 96
Self-citationSabet, A., Ezziddin, K., Pape, U., Reichman, K., Haslerud, T. M., Ahmadzadehfar, H., Biersack, H., Nagarajah, J., & Ezziddin, S. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2601-x · Cited by 93
Changing paradigms with molecular imaging of neuroendocrine tumors.
Hofman, M. S., & Hicks, R. J. (2012) · PubMed · Cited by 86
Self-citationUse of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
Hicks, R. J. (2010) · Cancer Imaging · doi:10.1102/1470-7330.2010.9007 · Cited by 86
Self-citationJackson, P. A., Beauregard, J., Hofman, M. S., Kron, T., Hogg, A., & Hicks, R. J. (2013) · Medical Physics · doi:10.1118/1.4824318 · Cited by 81
Self-citationHubble, D., Kong, G., Michael, M., Johnson, V., Ramdave, S., & Hicks, R. J. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1483-4 · Cited by 70
Self-citationKesavan, M., & Turner, J. H. (2016) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2035 · Cited by 69
Swärd, C., Bernhardt, P., Ahlman, H., Wängberg, B., Forssell-Aronsson, E. B., Larsson, M., Svensson, J. B., Norrlund, R. R., & Kölby, L. (2010) · World Journal of Surgery · doi:10.1007/s00268-009-0387-6 · Cited by 68
Brunner, P., Jörg, A.-C., Glatz, K., Bubendorf, L., Radojewski, P., Umlauft, M., Marincek, N., Spanjol, P.-M., Krause, T., Dumont, R. A., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3486-2 · Cited by 66
Brieau, B., Hentic, O., Lebtahi, R., Palazzo, M., Ben Reguiga, M., Rebours, V., Maire, F., Hammel, P., Ruszniewski, P., & Fenaux, P. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0543 · Cited by 64
Kong, G., Callahan, J., Hofman, M. S., Pattison, D. A., Akhurst, T. J., Michael, M., Eu, P., & Hicks, R. J. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3527-x · Cited by 60
Self-citationEffects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function
Teunissen, J. J. M., Krenning, E. P., de Jong, F. H., de Rijke, Y. B., Feelders, R. A., van Aken, M. O., de Herder, W. W., & Kwekkeboom, D. J. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1151-8 · Cited by 49
Self-citationMyeloid neoplasms after chemotherapy and PRRT: myth and reality
Bodei, L., Modlin, I. M., Luster, M., Forrer, F., Cremonesi, M., Hicks, R. J., Ezziddin, S., Kidd, M. S., & Chiti, A. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0258 · Cited by 42
Self-citationKashyap, R. K., Jackson, P. A., Hofman, M. S., Eu, P., Beauregard, J., Zannino, D., & Hicks, R. J. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2504-x · Cited by 41
Self-citationDumont, R. A., Seiler, D., Marincek, N., Brunner, P., Radojewski, P., Rochlitz, C. F., Müller‐Brand, J., Maëcke, H. R., Briel, M., & Walter, M. A. (2015) · Europe PMC (PubMed Central) · doi:10.7892/boris.67183 · Cited by 29
Hofman, M. S., & Hicks, R. J. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2621-6 · Cited by 29
Self-citationGiovacchini, G., Nicolas, G., Freidank, H., Mindt, T. L., & Forrer, F. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1826-9 · Cited by 27
Bushnell, D. L., Menda, Y., O’Dorisio, T. M., Madsen, M. T., Miller, S. C., Carlisle, T., Squires, S., Kahn, D. J., Walkner, W., Connolly, M., et al. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497804773391658 · Cited by 22
Cited by
Pavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,179
Self-citationStrosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R. P., Kunz, P., Hobday, T., Hendifar, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5865 · Cited by 390
Self-citationBaudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P. L., Frilling, A., de Herder, W. W., Hörsch, D., Knigge, U., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.003 · Cited by 270
Self-citationRadiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals.
Fani, M., Mansi, R., Nicolas, G. P., & Wild, D. (2022) · Cancers · doi:10.3390/cancers14051172 · Cited by 56
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., & Colao, A. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099840 · Cited by 37
Metadata
- Authors
- Hicks, R. J., Kwekkeboom, D. J., Krenning, E., Bodei, L., Grozinsky-Glasberg, S., Arnold, R., Borbath, I., Cwikla, J., Toumpanakis, C., Kaltsas, G., Davies, P., Hörsch, D., Tiensuu Janson, E., Ramage, J., & participants, A. O. A. C. C.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 105
- Issue
- 3
- Pages
- 295-309
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2663808291
- Cited by
- 336
- References
- 80
- FWCI
- 19.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.